Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
Thomas Martin(University of California, San Francisco), Sundar Jagannath(Mount Sinai Hospital), Yunsi Olyslager(Janssen (Belgium)), Joris Diels(Janssen (Belgium)), Katja Weisel(Universität Hamburg), Satish Valluri(Janssen (United States)), Keqin Qi(Janssen (United States)), Jesús G. Berdeja(Tennessee Oncology), Arnob Banerjee(Johnson & Johnson (United States)), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Jordan M. Schecter(Centro de Investigación del Cáncer), Concetta Crivera(Janssen (Belgium)), Maneesha Mehra(Janssen (United States)), Sandhya Nair(Janssen (Belgium)), Anil Londhe(Janssen (United States)), Martin Vogel(Janssen (United States)), Carolyn C. Jackson(Centro de Investigación del Cáncer), Amrita Krishnan(City of Hope), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 31
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k